FDA approves Botox for crow's feet

If you have a high school reunion coming up, here's a medical development that you may want to keep an eye on.

Federal regulators for the first time have approved Botox injections to treat crow's feet.

The Food and Drug Administration said Wednesday that Allergan's Botox Cosmetic injection is the first drug approved to treat the wrinkles that form on the outside edge of the eyes.

Allergan Inc. studied use of the drug in 833 adults with crow's feet who randomly received Botox or a sham injection. Patients who received Botox had fewer visible wrinkles than those who received the placebo drug.

The most common side effects seen in patients were swelling and excess liquid around the eyelids.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Botox developer rues missing out on billions

Feb 13, 2012

Botox developer Alan Scott says he rues the day he handed over rights to the best-selling wrinkle-smoothing drug to a US company for just $4.5 million, saying he might have become a billionaire.

US approves Botox for bladder control

Aug 24, 2011

The face-freezing pharmaceutical injection Botox gained another medical use on Wednesday when the US government approved it for use in some patients with overactive bladder.

FDA approves Botox for migraine headaches

Oct 15, 2010

(AP) -- Federal health officials approved the wrinkle-smoothing injection Botox for migraine headaches on Friday, giving drugmaker Allergan clearance to begin marketing its drug to patients with a serious history of the ...

Botox reduces wrinkles even in less frequent doses

Apr 26, 2010

Patients can decrease the frequency of Botox Cosmetic injections after approximately two years and still receive most of the same wrinkle-smoothing cosmetic benefits, according to new research at Oregon Health & Science University.

Recommended for you

Boxed warnings are common in novel therapeutics

12 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

13 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

14 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

warrenhenery
not rated yet Oct 10, 2013
It is indeed a good news for the fans of Botox NYC who want to look younger for the most part of their age. http://trifectamedspanyc.com/